SCHEMBL8358191

SCHEMBL8358191

C=CCC(C(=O)O)(c1ccccc1)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.67
TSHR P16473 1/20 0.67
HTT P42858 1/20 0.58
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 2/20 0.42
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CYP2C19 P33261 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
OPRM1 P35372 4/20 0.39
DRD3 P35462 3/20 0.39
DRD4 P21917 2/20 0.39
DRD2 P14416 1/20 0.39
MAPT P10636 1/20 0.39
HIF1A Q16665 1/20 0.38
AKT1 P31749 1/20 0.38
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19617612 0.86 ALDH1A1 (0.51) ALDH1A1TSHRHTTSMN1; SMN2MAPT
SCHEMBL7167864 0.85 HTT (0.69) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL8992450 0.83 ALDH1A1 (0.47) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL8661754 0.82 OPRM1 (0.57) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL7989858 0.82 ALDH1A1 (0.48) ALDH1A1TSHRHTTKMT2ACYP1A2
SCHEMBL15848242 0.80 ALDH1A1 (0.53) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL7715181 0.80 ALDH1A1 (0.67) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL7385780 0.80 ALDH1A1 (0.67) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL5325708 0.80 ALDH1A1 (0.67) ALDH1A1TSHRHTTKMT2AMEN1
SCHEMBL7769347 0.80 ALDH1A1 (1.00) ALDH1A1TSHRHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4103581-A None JP disclosed
US-12503458-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-12-23 US disclosed
US-20240425487-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-12-26 US disclosed
US-11897870-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University-Of The Commonwealth System Higher Education (US) 2024-02-13 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE Temple University--of the Commonwealth System of Higher Education 2022-05-05 US disclosed
EP-3738955-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE Temple University Of The Commonwealth System Of Higher Education (US) 2020-11-18 EP disclosed
EP-3738955-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE Temple University Of The Commonwealth System Of Higher Education (US) 2020-11-18 EP disclosed
US-20200317648-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-10-08 US disclosed
US-20200317648-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-10-08 US disclosed
WO-2014164756-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-10-09 WO disclosed
WO-1999029640-A2 COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF FIBROBLAST GROWTH FACTOR EISAI CO., LTD. (JP) 1999-06-17 WO disclosed
WO-1998050022-A1 DIPHENYLACETIC ACID DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS LOVESGROVE RESEARCH LIMITED (GB) 1998-11-12 WO disclosed
US-5192779-A Substituted-acetamide compound and a process for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-03-09 US disclosed
JP-H04103581-A 5-(1-IMIDAZOL)METHYL)-3,3-DISUBSTITUTED-2(3H)FURANONE DERIVATIVE MARION MERRELL DOW INC 1992-04-06 JP disclosed
US-5066680-A NOVEL SUBSTITUTED-ACETAMIDE COMPOUND AND A PROCESS FOR THE PREPARATION THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-19 US disclosed
EP-0455909-A2 5-[1-(Imidazol)methyl]-3,3-disubstituted-2(3H) furanone derivatives MARION MERRELL DOW INC. (US) 1991-11-13 EP disclosed
US-5064850-A Anticholenergic MARION MERRELL DOW INC. (US) 1991-11-12 US disclosed
US-5039691-A Anticholinergic agents MARION MERRELL DOW INC. (US) 1991-08-13 US disclosed
EP-0383256-A2 A novel substituted-acetamide compound and a process for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503458-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 ALDH1A1 2423/4885TSHR 238/4885HTT 158/4885
US-20200317648-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A ALDH1A1 2644/4885TSHR 237/4885HTT 248/4885
US-20220133713-A1 SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE SIGMAR1, TMEM97, OPRL1 ALDH1A1 2183/4885TSHR 323/4885HTT 929/4885
US-11897870-B2 5-hydroxytryptamine receptor 7 activity modulators and their method of use HTR7, HTR5A, HTR6 ALDH1A1 2423/4885TSHR 238/4885HTT 158/4885
US-20240425487-A1 NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE HTR7, HTR6, HTR5A ALDH1A1 2644/4885TSHR 237/4885HTT 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.